Cocaine Abuse Clinical Trial
Official title:
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.
Galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine users. The cognitive performance will be measured with the Stroop test and 3 Cambridge Neuropsychological Test Automated Battery (CANTAB) tests: Paired Associate Learning (PAL), Delayed Pattern Recognition Memory (PRM),and Rapid Visual Information Processing (RVIP). Performance on these tests has been shown to be impaired in abstinent cocaine users, compared to healthy controls. Galantamine, compared to placebo, will not be associated with any significant changes in mood. Monitoring of mood will be achieved with 3 mood scales: 1) Center for Epidemiologic Studies Depression (CES-D) scale, Positive and Negative Affect Schedule (PANAS) and the Profile of Mood States (POMS). Currently this study is completed, Patients are no longer being enrolled. There were 28 completers. This study has been published. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
| Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
| Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
| Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
| Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
| Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
| Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
| Recruiting |
NCT00439049 -
Substance Abuse Pre-Treatment Screening Study
|
||
| Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
| Completed |
NCT01401270 -
Prize Contingency Management for Cocaine-Dependent Methadone Patients
|
N/A | |
| Completed |
NCT00350610 -
Computer-Based Training in Cognitive Behavior Therapy
|
Phase 1 | |
| Recruiting |
NCT06177860 -
Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
|
||
| Completed |
NCT02393599 -
Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
|
Phase 1 | |
| Completed |
NCT02141620 -
n-Acetylcysteine and Cocaine
|
Phase 0 | |
| Recruiting |
NCT00218023 -
Medications for Stopping Cocaine Dependence and Preventing Relapse
|
Phase 2 | |
| Completed |
NCT00218075 -
Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
|
Phase 2 | |
| Recruiting |
NCT05857852 -
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
|
N/A | |
| Completed |
NCT00292123 -
Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
|
Phase 1 | |
| Completed |
NCT00318760 -
Effect of Clonidine on Responses to Imagery Scripts
|
Phase 1 | |
| Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 |